Diversity Supplement to Fate, Function and Genetic Engineering of Breast Milk Cells for Infant Therapy

Information

  • Research Project
  • 10406083
  • ApplicationId
    10406083
  • Core Project Number
    DP2HD098860
  • Full Project Number
    3DP2HD098860-01S1
  • Serial Number
    098860
  • FOA Number
    PA-21-071
  • Sub Project Id
  • Project Start Date
    9/1/2021 - 2 years ago
  • Project End Date
    6/30/2023 - 10 months ago
  • Program Officer Name
    ILEKIS, JOHN V
  • Budget Start Date
    9/1/2021 - 2 years ago
  • Budget End Date
    6/30/2023 - 10 months ago
  • Fiscal Year
    2021
  • Support Year
    01
  • Suffix
    S1
  • Award Notice Date
    8/26/2021 - 2 years ago

Diversity Supplement to Fate, Function and Genetic Engineering of Breast Milk Cells for Infant Therapy

PROJECT SUMMARY Each year, 15,000 infants die in the U.S. from diseases for which there are no effective therapies, and many more suffer through invasive procedures to address the diseases that are treatable. Here, we propose a non-invasive therapy based on the genetic engineering of breast milk cells to enable unprecedented production and delivery of therapeutics in infants. The approach is similar to the recently FDA-approved CAR-T therapy, except simpler, less invasive, and with broader potential use. Ultimately, we envision that cells will be isolated from freshly expressed milk, sorted by type, and transfected with RNA or DNA. Cells will then be reincorporated into milk for consumption. Each breast milk cell type has the potential for unique therapeutic functions: epithelial cells can operate as protein replacement ?factories?, immune cells can produce peptide antigens for vaccination or immunotherapy, and stem cells can be programmed through the expression of transcription factors for cell therapy. This proposal will take the first, most important steps in achieving our long-term therapeutic vision. First, we will establish a basic understanding of breast milk cell subsets, their biodistribution in mouse neonates, and their transport mechanisms. We will determine if breast milk cell uptake is facilitated by cell attributes, other milk components, and/or the nature of the neonatal gut. We will also establish breast milk cell persistence times in the neonate as a function of location. Several transfection methods, including viral, non-viral, and microfluidic systems will be tested for their ability to maximize protein output without compromising cell transport. Finally, we will pursue therapeutic applications informed by our fundamental studies, including protein replacement, vaccination, immunotherapy, and stem cell therapy. Initial successes will set the stage for follow-up studies in animal models of neonatal disease and the eventual non-invasive treatment of infants for whom there are no currently available therapies.

IC Name
EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT
  • Activity
    DP2
  • Administering IC
    HD
  • Application Type
    3
  • Direct Cost Amount
    75245
  • Indirect Cost Amount
    19645
  • Total Cost
    94890
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    865
  • Ed Inst. Type
    BIOMED ENGR/COL ENGR/ENGR STA
  • Funding ICs
    NICHD:94890\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
  • Study Section Name
  • Organization Name
    CARNEGIE-MELLON UNIVERSITY
  • Organization Department
    ENGINEERING (ALL TYPES)
  • Organization DUNS
    052184116
  • Organization City
    PITTSBURGH
  • Organization State
    PA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    152133815
  • Organization District
    UNITED STATES